Holen Sie sich die Stockscreener-App
0.2267
3.61%
-0.0085
VolitionRX Ltd Aktie (VNRX) Neueste Nachrichten
Volume Summary: Is now the right time to enter VolitionRx LimitedJuly 2025 Retail & Step-by-Step Trade Execution Guides - mfd.ru
VolitionRx nears 100 Nu.Q Discover clients, extends reach to Japan - Stock Titan
VolitionRx receives NYSE American non-compliance notice By Investing.com - Investing.com Australia
VolitionRx (VNRX) Plans to Offer Nearly 18 Million Shares - GuruFocus
VolitionRx (VNRX) Faces NYSE American Compliance Challenge - GuruFocus
VolitionRx Gets NYSE American Non-Compliance Notice for Failing Equity Requirements - marketscreener.com
VolitionRx Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
VolitionRx stock gets 'below compliance' tag after NYSE warning - Stock Titan
Volume Report: Is VolitionRx Limited affected by consumer sentimentJuly 2025 Earnings & Intraday High Probability Setup Alerts - baoquankhu1.vn
VolitionRx Prepares French Reimbursement Submission for Nu.Q Cancer Blood Tests - MEXC
VolitionRx (VNRX) Moves Forward with French Reimbursement Submis - GuruFocus
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays - Yahoo Finance
Aug Wrap: Is VolitionRx Limited benefiting from innovation trendsMarket Activity Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
VNRX: D. Boral Capital Maintains Buy Rating and $3 Price Target - GuruFocus
VolitionRx (VNRX) Expands Nu.Q Vet Cancer Test Reach in U.S. and Asia - GuruFocus
Dog cancer blood test expands to all 50 states and parts of Asia - Stock Titan
VolitionRX (VNRX) Receives Buy Rating, Price Target Maintained a - GuruFocus
Why VolitionRx Limited stock is popular among millennialsEarnings Growth Report & Expert Curated Trade Setups - Улправда
VolitionRx Signs Amended Securities Purchase Agreement With Lind Global Asset Management XII - TradingView — Track All Markets
Is VolitionRx Limited stock trading near support levels2025 Key Lessons & Growth Oriented Trading Recommendations - Улправда
Volitionrx stock soars after feline cancer test shows high accuracy By Investing.com - Investing.com Nigeria
VolitionRx Limited Announces Breakthrough Clinical Data for Nu.Q Vet Cancer Test in Cats - marketscreener.com
VolitionRx secures $2 million in additional funding through convertible note By Investing.com - Investing.com India
VolitionRX announces breakthrough clinical data for Nu.Q® veterinary cancer test in cats - MarketScreener
VolitionRx secures $2M financing through amended securities agreement; shares up - MSN
VolitionRX Ltd enters amended securities purchase agreement - marketscreener.com
VolitionRx Secures $2.0 Million in Funding - Yahoo Finance
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats - marketscreener.com
A simple blood test that can spot lymphoma in cats may be on the way - Stock Titan
VolitionRx downgraded to Hold from Buy at Maxim - MSN
How buybacks impact VolitionRx Limited stock valueJuly 2025 Update & Entry and Exit Point Strategies - Улправда
How VolitionRx Limited stock performs during Fed tightening cyclesJuly 2025 Pullbacks & Fast Gain Swing Trade Alerts - Улправда
VolitionRX (VNRX) Target Price Slashed by D. Boral Capital | VNR - GuruFocus
Simple blood tests for cancer and sepsis move closer to hospitals in 2025 - Stock Titan
VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment - MSN
VolitionRx to eliminate veterinary CEO role as part of cost-realignment - Investing.com Australia
VolitionRx Announces Termination of CEO Position at Subsidiary - TradingView — Track All Markets
VolitionRx (VNRX) to end Volition Veterinary CEO role, retain Dr. Butera as consultant - Stock Titan
VolitionRx (VNRX) Unveils Innovative Cancer Detection Method - GuruFocus
Volition (NYSE AMERICAN: VNRX) posts 100% sensitivity in 70-person liquid biopsy study - Stock Titan
VolitionRx’s (VNRX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Why VolitionRX Limited stock is a strong buy call2025 Pullback Review & Risk Controlled Daily Plans - Newser
VolitionRx’s Sepsis Biomarker Selected for French National Healthcare Initiative - citybuzz
VolitionRX (VNRX): Analyst Maintains 'Buy' Rating Amidst Stable Price Target | VNRX Stock News - GuruFocus
VolitionRx (NYSE AMERICAN: VNRX) named sole biomarker partner in €6.3M DETECSEPS sepsis detection program - Stock Titan
How VolitionRx Limited stock valuations compare to rivalsGap Up & Fast Entry Momentum Trade Alerts - Newser
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis - Yahoo Finance
VolitionRx (NYSE:VNRX) Lowered to “Hold” Rating by Maxim Group - Defense World
How VolitionRx Limited stock reacts to job market data2025 Market Sentiment & Consistent Growth Equity Picks - Newser
VNRX: Maxim Group Downgrades VolitionRX to Hold | VNRX Stock New - GuruFocus
Healthy Upside Potential: VolitionRX Ltd (VNRX) - Setenews
VolitionRx (VNRX) Insider Trading Activity 2025 - MarketBeat
Why millennials buy VolitionRX Limited stockQuarterly Earnings Summary & AI Optimized Trade Strategies - moha.gov.vn
VolitionRX (VNRX) Analyst Rating Update: Maintain 'Buy' with $5 Target | VNRX Stock News - GuruFocus
VolitionRX Ltd (VNRX) is looking forward to a strong quarter - Setenews
0.00%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):